Table 2.
Studies on prophylactic cranial irradiation non-small cell lung carcinoma (NSCLC)
| Study/Date | N | Primary treatment | Stage | Dose [Gy] | BM (%) | Median DFS | Median OS/% | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCI | Obs | p | PCI | Obs | p | PCI | Obs | p | |||||
| Umsawasdi (MDACC trial) 1984 [39] | 97 | RT CT | III | 30 (3Gy × 10) | 4 | 27 | 0.002 | NA | 3 y: 22% | 23.5% | NA | ||
| Russell (RT OG 8403) 1991 [43] | 187 | RT only | I/III. Inoperable NSCLC | 30 (3Gy × 10) | 9 | 19 | 0.100 | NA | 8.4 m | 8.1 m | 0.36 | ||
| Li 2014 [40] | 156 | Sx + CT | IIIA–N2 | 30 (3Gy × 10) | 20.3 | 50 | < 0.001 | 28.5 m | 21.2 m | 0.037 | 31.2 m | 27.4 m | 0.310 |
| 5 y: 26.1% | 18.5% | ||||||||||||
| De Ruysscher (NVALT -11/DLCR G-02) 2018 [49] | 175 | RT + CT or Sx + RT/CT | III | 30 (2.5 Gy × 12) | 7 | 27.2 | < 0.001 | 12.3 m | 11.5 m | 0.17 | 24.2 m | 21.2 m | 0.56 |
| Gore/Sun (RT OG 0214) 2019 [101, 102] | 340 | RT/Sx ± CT | IIIA/B | 30 (2 Gy × 15) | 16.7 | 28.3 | 0.004 | 15 m | 12 m | 0.03 | 28 m | 25 m | 0.12 |
| 5 y: 19% | 16% | 5 y: 24.7% | 26% | ||||||||||
| 10 y: 12.6% | 7.5% | 10 y: 18% | 13.3% | ||||||||||
N — number of patients; PCI — prophylactic cranial irradiation; Obs — observation group; BM — incidence of brain metastases; DFS — disease free survival; RT — radiotherapy; Sx — surgery; CT — chemotherapy; y — years; m — months; NA — not available